GuruFocus Updates (Free subscription) | 05/08/2008
Healthcare stocks have been hit hard lately, even after the recent recovery. Time to dive in for bargains? Edward Owens, arguably the best heathcare investor, is buying beaten down HMO and pharmas. These are his buys and sells during the second quarter of 2008.
PR News Wire (Free subscription) | 07/07/2008
WHITE PLAINS, N.Y., July 7 /PRNewswire/ -- The Leukemia & Lymphoma Society has awarded a $550,000 grant to Jonathan Friedberg M.D., M.M.Sc., of the James P. Wilmot Cancer Center at the University of Rochester Medical Center. Millennium Pharmaceuticals, The Takeda Oncology Company, of Cambridge, Mass., is funding the first two years of the five-year program. The Scholar in Clinical Research Career...
Red Orbit (Free subscription) | 21/06/2008
CAMBRIDGE, Mass. and OSAKA, Japan, June 20 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) today announced that the U.S.
The Earth Times Online Newspaper (Free subscription) | 31/05/2008
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patien...
Red Orbit (Free subscription) | 31/05/2008
CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and dexamethasone (VcD) to vincristine, adriamycin and dexamethasone (VAD).
ETF Trends (Free subscription) | 10/05/2008
Biotechnology is rising up to analyst's predictions that a near future run could send related stocks and exchange traded funds (ETFs) up. The latest April announcement that Takeda Pharmaceutical would buy Massachusetts-based Millennium Pharmaceuticals (MLMN) for $8.8 billion sent the...
Market Wire - Investment Opinion (Free subscription) | 09/05/2008
LONDON (MARKET WIRE)
Seeking Alpha (Free subscription) | 09/05/2008
Don Dion submits: The April announcement that Japanese drug maker Takeda Pharmaceutical would buy Massachusetts-based Millennium Pharmaceuticals (MLNM) (which sells the anticancer injection Velcade) for $8.8 billion sent Millennium shares markedly higher. The acquisition also lifted expectations for a run of biotech M&A, boosting much of the sector. Complete Story ยป
The Earth Times Online Newspaper (Free subscription) | 09/05/2008
OSAKA, Japan, and CAMBRIDGE, Mass., May 9 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited, Takeda , and Millennium Pharmaceuticals, Inc., Millennium today announced the succe...
The Earth Times Online Newspaper (Free subscription) | 09/05/2008
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 7.7 percent fall in annual operating profit on Friday and forecast a sharp drop for the current year on costs for its $8.8 billion purchase of U.S. biotech firm Millennium Pharmaceuticals.
Reuters (Free subscription) | 09/05/2008
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 7.7 percent fall in annual operating profit on Friday and forecast a sharp drop for the current year on costs for its $8.8 billion purchase of U.S. biotech firm Millennium Pharmaceuticals.
Market Wire - Investment Opinion (Free subscription) | 06/05/2008
WESTON, FL (MARKET WIRE) Wall Street News Alert's "stocks to watch" this morning are: Oncolin Therapeutics (OTCBB: OCOL), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM), Gilead Sciences, Inc. (NASDAQ: GILD).
Patent Docs (Free subscription) | 03/05/2008
By Donald Zuhn -- In March, we reported on the lobbying expenditures for a number of biotech and pharmaceutical companies in 2007. For example, we noted that Millennium Pharmaceuticals had spent $1.28 million, Genentech $1.8 million, and AstraZeneca $4.1 million in 2007. Topping each of these companies, however, was Abbott...
The Boston Business Journal (Free subscription) | 29/04/2008
Government regulators in the United States, Austria and Germany have cleared the planned $8.8 billion sale of Millennium Pharmaceuticals Inc. to Japanese drug maker Takeda Pharmaceutical Co. Ltd.
Fiercebiotech (Free subscription) | 29/04/2008
Mark Levin earned a reputation for a colorful personality with an incredible knack for raising cash as co-founder of Millennium Pharmaceuticals. Two weeks ago, Takeda helped seal Levin's reputation Read more...
